Increase viable CHO cell density in commercial available cell culture medium by supplementation with recombinant insulin

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Novo Nordisk Pharmatech A/S, Københavnsvej 216, 4600 Koege, Denmark
Tel: +45 5667 1000
Fax: +45 5667 1001
Email: [email protected]

Company website

Novo Nordisk Pharmatech A/S was established in 1949. It is the leading worldwide supplier of recombinant insulin, which is sourced directly from Novo Nordisk, the world’s largest producer. Its recombinant insulin is a key component in serum free growth media for mammalian cells and approved by regulatory bodies worldwide, including FDA and EMA. The company’s products are manufactured to cGMP standards, and have distinguished itself for:

- Global regulatory compliance
- Consistent high quality
- Extensive regulatory documentation
- Continuous availability
- Secure global supply chain
- High levels of service and support

Increase viable CHO cell density in commercial available cell culture medium by supplementation with recombinant insulin

Please log in for more information